Eugene Kim, MD
Critical Care Medicine · Waxhaw, NCNPI 1568410827
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 35.4% of the total. Reporting peaked in 2024 at $471 and has fallen 71.6% since, to $134 in 2025.
Across 44 payments — averaging $29.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$461
- Resmed Corp$131
- Eisai Inc.$116
- Merck$97
- Idorsia Pharmaceuticals US Inc$82
- Sanofi$50
- plus $362 from 13 others
What the payments were for
- Food & beverage$1,300100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 13 | $461 |
| Resmed Corp | 1 | $131 |
| Eisai Inc. | 1 | $116 |
| Merck | 5 | $97 |
| Idorsia Pharmaceuticals US Inc | 4 | $82 |
| Sanofi | 2 | $50 |
| AstraZeneca | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 1 | $37 |
| Bayer | 2 | $36 |
| Boehringer Ingelheim | 1 | $32 |
| GSK | 2 | $31 |
| Novartis | 2 | $29 |
| Lilly USA, LLC | 1 | $25 |
| Grifols USA, LLC | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,300 in reported general payments places this provider in the 75th percentile of 190 critical care medicine providers in North Carolina.
See all critical care medicine providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 346 | $281,071 |
| WakixPitolisant Hcl | 11 | $174,923 |
| NucalaMepolizumab | 38 | $138,488 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $133,391 |
| Fasenra PenBenralizumab | 18 | $102,304 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 50 | $36,599 |
| BelsomraSuvorexant | 54 | $26,071 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $14,913 |
| Incruse ElliptaUmeclidinium Bromide | 33 | $14,517 |
| Spiriva RespimatTiotropium Bromide | 16 | $14,336 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $13,969 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $13,172 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $12,562 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 379 | $11,197 |
| AdderallDextroamphetamine/Amphetamine | 12 | $7,594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $31 | $486,792509 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $41 | $28,88269 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $32 | $27,50840 claims |
| MerckBelsomra | $97 | $26,07154 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $13 | $89619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 190 critical care medicine providers in North Carolina.
Other critical care medicine in Waxhaw
- Alexis SmithHuntersville$726K
- Rabih BecharaCharlotte$453K
- Ashish KhannaWinston Salem$364K
- Alan HeffnerCharlotte$326K
- Daniel FeinsteinPinehurst$213K
- Daniel FoxRaleigh$133K
- Hassan YousafWinston Salem$97K
- Neil MacintyreDurham$70K
- Andrea MacdonaldRaleigh$67K
- John DotyCharlotte$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.